Table 2.
Anti-SARS-CoV-2 seroprevalence related to health status and severity of last flu-like illness.
| Category | Participants | ELISA | Immunoblot | ||
|---|---|---|---|---|---|
| Positive Results |
Seroprevalence (95% CI) | Positive Results |
Seroprevalence (95% CI) | ||
| Chronic diseases | |||||
| None | 964 | 16 | 1.66% (1.02–2.70) |
11 | 1.14% (0.64–2.03) |
| CS-CDs | 185 | 1 | 0.54% (0.03–3.00) |
1 | 0.54% (0.03–3.00) |
| RS-CDs | 78 | 3 | 3.85% (1.05–10.71) |
0 | 0.00% (0.00–4.69) |
| I-CDs | 8 | 0 | 0.00% (0.00–32.44) |
0 | 0.00% (0.00–32.44) |
| CKD | 1 | 0 | 0.00% (0.00–94.87) |
0 | 0.00% (0.00–94.87) |
| DT-CDs | 23 | 0 | 0.00% (0.00–14.31) |
0 | 0.00% (0.00–14.31) |
| A-CDs | 170 | 4 | 2.35% (0.90–5.76) |
1 | 0.59% (0.03–3.26) |
| NeoD | 5 | 0 | 0.00% (0.00–43.45) |
0 | 0.00% (0.00–43.45) |
| MetD | 50 | 1 | 2.00% (0.10–10.50) |
1 | 2.00% (0.10–10.50) |
| MentD | 29 | 0 | 0.00% (0.00–11.70) |
0 | 0.00% (0.00–11.70) |
| Severity of flu-like illness in the last 9 months before serological tests | |||||
| No symptoms |
260 | 8 | 3.08% (1.57–5.95) |
5 | 1.92% (0.82–4.42) |
| Mild | 454 | 5 | 1.10% (0.42–2.30) |
4 | 0.88% (0.34–2.24) |
| Moderate | 720 | 12 | 1.67% (0.96–2.89) |
5 | 0.69% (0.30–1.62) |
| Severe | 66 | 0 | 0.00% (0.00–5.50) |
0 | 0.00% (0.00–5.50) |
CDs—chronic diseases; CS-CDs—circulatory system CDs, i.e., hypertension; RS-CDs—respiratory system CDs, i.e., asthma; I-CDs—infectious CDs, i.e., HIV/AIDS; CKD—chronic kidney disease; DT-CDs—digestive track CDs, i.e., Crohn disease; A-CDs—autoimmunological chronic diseases, i.e., allergies; NeoD—neoplasmatic diseases, i.e., cancer; MetD—metabolic diseases, i.e., diabetes; MentD—mental disorders, i.e., depression.